Marilyn Angela McLaughlin MD

Myeloproliferative Disorder Hematology-Oncology

Physician

15 Hospital DriveYork, ME 03909
Phone+1 207-351-3777
Fax+1 207-351-3788

Dr. McLaughlin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McLaughlin's full profile Already have an account?

Education & Training

Westchester Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Westchester Medical CenterResidency, Internal Medicine, 1993 - 1996
Rutgers New Jersey Medical SchoolClass of 1993

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

ME State Medical License 2014 - 2028
NY State Medical License 1999 - 2027
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification iKnowMed Generation 2, McKesson, 2016
CMS Meaningful Use Stage 1 Certification iKnowMed Generation 2, McKesson, 2016
CMS Meaningful Use Stage 1 Certification iKnowMed Generation 2, McKesson, 2016

Clinical Trials

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
TERMINATED
PHASE3
The National Myelodysplastic Syndromes (MDS) Study Start of enrollment: 2016 Jun 13
COMPLETED
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

131 citations
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer
Jeffrey I. Zwicker, Benjamin L. Schlechter, Jack D. Stopa, Howard A. Liebman, Anita Aggarwal
JCI Insight. 2019-02-21

Press Mentions

York Hospital CEO Dr. Patrick Taylor Meets with Local LeadersMay 11th, 2021
York Hospital Receives Zero COVID Shots This Week for Phase 1b RecipientsJanuary 26th, 2021